Minocycline-induced lupus in adolescents: Clinical implications for physical therapists

Journal of Orthopaedic and Sports Physical Therapy

Volumn 37, Issue 2, 2007, Pages 65-71

  Geddes, Rita ^a,b,c,d  

^a Bucks County Intermediate Unit   (United States)

^b Sports and Back Rehabilitation Inc   (United States)

^c WIDENER UNIVERSITY   (United States)

^d NONE   (United States)

Author keywords

Adverse reaction; Arthralgia; Myalgia; Pharmacovigilance

Indexed keywords

EID: 33847702199     PISSN: 01906011     EISSN: None     Source Type: Journal    
DOI: 10.2519/jospt.2007.2312     Document Type: Article

References (50)

1. Akin E, Miller LC, Tucker LB. Minocycline-induced lupus in adolescents. Pediatrics. 1998;101:926-928.
2. American Physical Therapy Association. Guide to Physical Therapist Practice. Alexandria, VA: American Physical Therapy Association; 2003;31-42.
3. American Physical Therapy Association. Vision Sentence for Physical Therapy 2020 and Vision Statement for Physical Therapy 2020 (HOD 06-00-24-35). Available at: http://www.apta.org/AM/Template.cfm?Section= About_APTA&TEMPLATE=/CM/ContentDisplay.cfm&CONTENTID=19078. Accessed September 1, 2005.
4. Balestrero S, Ciambellotti A, Parodi A, Rebora A. Minocycline-induced lupus-like syndrome. Int J Dermatol. 2001;40:474-475.
5. Betts EF, Betts JJ, Betts CJ. Pharmacologie management of hyperglycemia in diabetes mellitus: implications for physical therapy. Phys Ther. 1995;75:415-425.
6. Bhat G, Jordan J Jr, Sokalski S, et al. Minocycline-induced hepatitis with autoimmune features and neutropenia. J Clin Gastroenterol. 1998;27:74-75.
7. Biederman RE. Pharmacology in rehabilitation: nonsteroidal anti-inflammatory agents. J Orthop Sports Phys Ther. 2005;35:356-367.
8. Boissonnault WG. Primary Care for the Physical Therapist Examination and Triage. St Louis, MO: Elsevier Saunders; 2005;161, 309-322.
9. Boissonnault WG, Meek PD. Risk factors for anti-inflammatory-drug- or aspirin-induced gastrointestinal complications in individuals receiving outpatient physical therapy services. J Orthop Sports Phys Ther. 2002;32:510-517.
10. Byrne PA, Williams BD, Pritchard MH. Minocycline-related lupus. Br J Rheumatol. 1994;33:674-676.
11. Christodoulou CS, Emmanuel P, Ray RA, Good RA, Schnapf BM, Cawkwell GD. Respiratory distress due to minocycline-induced pulmonary lupus. Chest. 1999;115:1471-1473.
12. Ciccone CD. Basic pharmacokinetics and the potential effect of physical therapy interventions on pharmacokinetic variables. Phys Ther. 1995;75:343-351.
13. Ciccone CD. Current trends in cardiovascular pharmacology. Phys Ther. 1996;76:481-497.
14. Crosson J, Stillman MT. Minocycline-related lupus erythematosus with associated liver disease. J Am Acad Dermatol. 1997;36(pt 2):867-868.
15. Dunphy J, Oliver M, Rands AL, Lovell CR, McHugh NJ. Antineutrophil cytoplasmic antibodies and HLA class II alleles in minocycline-induced lupus-like syndrome. Br J Rheumatol. 2000;142:461-467.
16. Eichenfeld AH. Minocycline and autoimmunity. Curr Opin Pediatr. 1999;11:447-456.
17. Elkayam O, Levartovsky D, Brautbar C, et al. Clinical and immunological study of 7 patients with minocycline-induced autoimmune phenomena. Am J Med. 1998;105:484-487.
18. Elkayam O, Yaron M, Caspi D. Minocycline induced arthritis associated with fever, livedo reticularis, and pANCA. Ann Rheum Dis. 1996;55:769-771.
19. Elkayam O, Yaron M, Caspi D. Minocycline-induced autoimmune syndromes: an overview. Semin Arthritis Rheum. 1999;28:392-397.
20. Farver DK. Minocycline-induced lupus. Ann Pharmacother. 1997;31:1160-1163.
21. Gallichio JE. Pharmacologic management of spasticity following stroke. Phys Ther. 2004;84:973-981.
22. Golstein PE, Deviere J, Cremer M. Acute hepatitis and drug-related lupus induced by minocycline treatment. Am J Gastroenterol. 1997;92:143-146.
23. Gordon MM, Porter D. Minocycline induced lupus: case series in the West of Scotland. J Rheumatol. 2001;28:1004-1006.
24. Gough A, Chapman S, Wagstaff K, Emery P, Elias E. Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome. BMJ. 1996;312:169-172.
25. Goulden V. Guidelines for the management of acne vulgaris in adolescents. Pediatr Drugs. 2003;5:301-313.
26. Grim SA, Romanelli F, Jennings PR, Ofotokun I. Late-onset drug fever associated with minocycline: case report and review of the literature. Pharmacotherapy. 2003;23:1659-1662.
27. Gulick D. Ortho Notes. Philadelphia, PA: FA Davis Co Publishers; 2005.
28. Hall CM, Brody LT. Therapeutic Exercise. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2005;680-685.
29. Hess E. Drug-related lupus. N Engl J Med. 1988;318:1460-1462.
30. Knights SE, Leandro MJ, Khamashta MA, Hughes GR. Minocycline-induced arthritis. Clin Exp Rheumatol 1998;16:587-590.
31. Knowles SR, Shapiro L, Shear NH. Serious adverse reactions induced by minocycline: report of 13 patients and review of the literature. Arch Dermatol. 1996;132:934-939.
32. Landau M, Shachar E, Brenner S. Minocyclineinduced serum sickness-like reaction. J Eur Acad Dermatol Venereol. 2000;14:65-68.
33. Lawrenson RA, Seaman HE, Sundstrom A, Williams TJ, Farmer RD. Liver damage associated with minocycline use in acne: a systematic review of the published literature and pharmacovigilance data. Drug Saf. 2000;23:333-349.
34. Lawson TM, Amos N, Bulgen D, Williams BD. Minocycline-induced lupus: clinical features and response to rechallenge. Rheumatology (Oxford). 2001;40:329-335.
35. Marzo-Ortega H, Misbah S, Emery P. Minocydine induced autoimmune disease in rheumatoid arthritis: a missed diagnosis? J Rheumatol. 2001;28:377-378.
36. Masson C, Chevailler A, Pascaretti C, Legrand E, Bregeon C, Audran M. Minocycline related lupus. J Rheumatol. 1996;23:2160-2161.
37. Matsuura I Shimizu Y, Fujimoto H, Miyazaki T, Kano S. Minocycline-related lupus [letter]. Lancet. 1992;340:1553.
38. McHugh NJ. Minocycline-induced lupus and autoimmune phenomena. Lupus. 1999;8:417-418.
39. Peel C, Mossberg KA. Effects of cardiovascular medications on exercise responses. Phys Ther. 1995;75:387-396.
40. Riddle DL, Wells PS. Diagnosis of lower-extremity deep vein thrombosis in outpatients. Phys Ther. 2004;84:729-735.
41. Sarzi-Puttini P, Atzeni F, Capsoni E, Lubrano E, Doria A. Drug-induced lupus erythematosus. Autoimmunity. 2005;38:507-518.
42. Schlienger RG, Bircher AJ, Meier CR. Mino cycline-induced lupus: a systematic review. Dermatology. 2000;200:223-231.
43. Shapiro LE, Knowles SR, Shear NH. Comparative safety of tetracycline, minocycline, and doxycycline. Arch Dermatol. 1997;133:1224-1230.
44. Shepherd J. Severe complication of a commonly prescribed drug: minocycline-induced lupus. J Am Board Fam Pract. 2002;15:239-241.
45. Singer SJ, Piazza-Hepp TD, Girardi LS, et al. Lupuslike reaction associated with minocycline. JAMA. 1997;277:295-296.
46. Somech R, Arav-Boger R, Assia A, Spirer 2, Jurgenson U. Complications of minocycline therapy for acne vulgaris: case reports and review of the literature. Pediatr Dermatol. 1999;6:469-472.
47. Sturkenboom MC, Meier CR, Jick H, Stricker BH. Minocycline and lupuslike syndrome in acne patients. Arch Intern Med. 1999;159:493-497.
48. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification on systemic lupus erythematosus. Arthritis Rheum. 1982;25:1271-1277.
49. Teitelbaum JE, Perez-Atayde AR, Cohen M, Bousvaros A, Jonas MM. Minocycline-related autoimmune hepatitis: case series and literature review. Arch Pediatr Adolesc Med. 1998;152:1132-1136.
50. Tournigand C, Genereau T, Prudent M, Diemert MC, Herson S, Chosidow O. Minocycline-induced clinical and biological lupus-like disease. Lupus. 1999;8:773-774.